Zura Bio Ltd (ZURA) stock
Close on Nov 18, 2026Market cap $92.96MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $92.96M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -69.86%
Fundamentals
- Net income
- -$93.53M
- EPS, diluted
- -$1.11
- Free cash flow
- -$64.94M
- Diluted shares
- 128M
Trading
- Next earnings
- Mar 18, 2027 (estimated, during market hours)
- Previous close
- $1.03
- Open
- $1.01
- Day's range
- $0.94 – $1.05
- Volume
- 3,028,490
- Average volume (20 days)
- 7,771,853
- 52-week range
- $0.93 – $7.44
- RSI (14 days)
- 24.5
- Volatility (1 year)
- 109.1%
- Relative volume
- 0.92×
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZURA | S&P 500 | Difference | ZURA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -75.1% | -4.3% | −70.8 pts | ||
| 3 months | -83.3% | -4.6% | −78.7 pts | ||
| Year to date | -81.6% | +7.9% | −89.5 pts | ||
| 1 year | -74.8% | +11.8% | −86.6 pts | ||
| 3 years | -77.2% | +68.0% | −145.1 pts | -38.9% | +18.9% |
| 5 years | -90.3% | +66.2% | −156.5 pts | -37.2% | +10.7% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zura Bio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Update
- Results
- Results
About Zura Bio
Biological Products, (No Diagnostic Substances)
Zura Bio is a clinical-stage biotechnology company focused on developing therapies for individuals suffering from autoimmune and inflammatory disorders. The company’s pipeline comprises three licensed drug candidates: tibulizumab, a bispecific antibody designed to inhibit both IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7 receptor alpha; and torudokimab, a monoclonal antibody directed against IL-33. Rather than serving commercial customers, the firm evaluates its experimental treatments in adult clinical trial participants, with tibulizumab undergoing evaluation for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.
Company profile, executives and historyZura Bio stock: common questions
What is Zura Bio's stock price?
ZURA closed at $0.97 on Nov 18, 2026, down 6.75% on the day. Over the past 52 weeks it traded between $0.93 and $7.44.
What is Zura Bio's market cap?
Zura Bio was worth $92.96M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is ZURA's P/E ratio?
Zura Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.11), so it has no meaningful P/E ratio.
Does Zura Bio pay a dividend?
No. Zura Bio has not paid a cash dividend over the last twelve months.
When does Zura Bio report earnings next?
Zura Bio is expected to report Q4 FY2026 results on Mar 18, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ZURA stock performed over the past year?
Including dividends, ZURA returned -74.8% over the past year, against +11.8% for the S&P 500.
How many ZURA shares are sold short?
8M shares were sold short at the latest FINRA report, 14.66% of the float, or 1.8 days of average trading volume.
Who are Zura Bio's competitors?
Companies most similar to Zura Bio by business, industry and size include KYMR, CGEM, IMA, IMVT, JSPR.
See a number that looks wrong?